Search results
Author(s):
Amarinder Bindra
,
Shelley A Hall
Added:
3 years ago
After a drought in viable new therapies for more than a decade, two new drugs for use in heart failure patients were approved by the US Food and Drug Administration (FDA) in 2015. These drugs represent two new classes of agents in the heart failure space: a combined angiotensin receptor-neprilysin inhibitor (ARNI) (sacubitril/valsartan; brand name Entresto®, Novartis) and a sinoatrial node…
View more
Author(s):
Gurushankar Govindarajan
,
James R Sowers
,
Craig S Stump
Added:
3 years ago
There has been an increase in the prevalence of diabetes mellitus over the past 40 years, both in the US and worldwide. The worldwide prevalence of diabetes in 2000 was approximately 2.8% and is estimated to grow to 4.4% by 2030. This translates to a projected rise of diabetes from 171 million in 2000 to well over 350 million in 2030. The epidemic of diabetes will continue to rise as there is…
View more
Author(s):
Darwin Jeyaraj
,
David S Rosenbaum
Added:
3 years ago
Heart disease is the leading cause of death in the US with 700,000 deaths annually, of which 460,000 are attributable to sudden cardiac death (SCD). SCD is usually attributed to ventricular fibrillation (VF). Despite recent reductions in cardiac mortality from other causes, the incidence of SCD remains high with minimal decline in the last decade. The large majority of patients who suffer life…
View more
Author(s):
David S Rosenbaum
Added:
3 years ago
Heart disease is the leading cause of death in the US with 700,000 deaths annually, of which 460,000 are attributable to sudden cardiac death (SCD).1,2 SCD is usually attributed to ventricular fibrillation (VF). Despite recent reductions in cardiac mortality from other causes, the incidence of SCD remains high with minimal decline in the last decade. The large majority of patients who suffer life…
View more
Author(s):
Domenic A Sica
Added:
3 years ago
Hypertension is a major cause of morbidity and mortality worldwide.1–3 In the US, around 25% of the adult population has a blood pressure (BP) of ≥140/90mmHg, which is the defined cut-off value for hypertension.3 Although there are many effective pharmacotherapies available, many patients are not adequately controlled on their current antihypertensive regimens. The National Health and Nutrition…
View more
Author(s):
Aarti Asnani
,
Randall T Peterson
Added:
3 years ago
Survival rates among patients diagnosed with cancer have improved dramatically over the past few decades. In 2016, there were an estimated 16 million cancer survivors in the United States, a number expected to increase to 20 million over the subsequent decade.1 One-third of these patients will survive at least 5 years after their initial cancer diagnosis, largely due to cancer therapies that are…
View more
Author(s):
Deepak L Bhatt
,
Anna Meta Dyrvig Kristensen
,
Manan Pareek
,
et al
Added:
3 years ago
Hypertension is an important contributor to global morbidity and mortality and is a major burden on healthcare systems.1,2 More than 20% of the world’s population has high blood pressure when defined by conventional criteria: systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg.3,4 Even with therapeutic lifestyle and pharmacological measures, blood pressure remains poorly…
View more
Author(s):
Ahmad Masri
Added:
10 months ago
ESC-HFA 23 — We are joined by Dr Ahmad Masri (Oregon Health & Science University Medical Group, US) to discuss the findings from REDWOOD-HCM cohort 4 (NCT04219826).
This study assessed the safety and tolerability of the selective inhibitor of cardiac myosin, aficamten (Cytokinetics) in patients with symptomatic nHCM. Cohort 4 included 41 patients. The data presented at HFA 23 shows that…
View more
Author(s):
Sara Saberi
Added:
1 year ago
HFSA 2022 — Dr Sara Saberi (University of Michigan School of Medicine, US) joins us to talk about the findings of the REDWOOD-HCM OLE. This 5-year extension study showed improvement in KCCQ scores in patients with obstructive hypertrophic cardiomyopathy (HCM) treated with aficamten (Cytokinetics), a novel cardiac myosin inhibitor (NCT04219826).
Questions
1. What are some of the unmet needs in…
View more
Author(s):
Bertram Pitt
Added:
3 years ago
The therapy of patients with chronic heart failure (HF) due to systolic left ventricular dysfunction (SLVD) continues to evolve. There is agreement that all patients with HF due to SLVD should be treated with an angiotensin converting enzyme inhibitor (ACE-I) and a beta-adrenergic receptor blocking agent (BB) unless contraindicated or not tolerated. The role of angiotensin receptor blocking…
View more